Randomized, placebo-controlled trial of saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy

Cancer

Volumn 109, Issue 2, 2007, Pages 322-331

  Peterson, Douglas E ^a   Jones, James B ^b   Petit II, Robert G ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

Breast cancer; Chemotherapy; Glutamine; Mucotoxic; Oral mucositis; Saforis

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASCORBIC ACID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; GLUTAMINE; METOCLOPRAMIDE; ONDANSETRON; PLACEBO; PREDNISOLONE; SAFORIS; UNCLASSIFIED DRUG;

ADULT; ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; LEUKOPENIA; MAJOR CLINICAL STUDY; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; ORAL MUCOSITIS ASSESSMENT SCALE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; STOMATITIS; TREATMENT OUTCOME; VOMITING; WEAKNESS; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMINE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; STOMATITIS; TREATMENT OUTCOME;

EID: 33846213104     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22384     Document Type: Article

References (35)

1. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100:2026-2046.
2. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995-2025.
3. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98:1531-1539.
4. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201-2205.
5. Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol. 2005;23:8500-8511.
6. Bower JE. Prevalence and causes of fatigue after cancer treatment: the next generation of research. J Clin Oncol. 2005;23:8280-8282.
7. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97:2919-2925.
8. Kepivance (palifermin) [package insert]. Thousand Oaks, CA: Amgen Inc; 2004-2005.
9. Wernerman J, Hammarqvist F, Glutamine: a necessary nutrient for the intensive care patient. Int J Colorectal Dis. 1999;14:137-142.
10. Mates JM, Perez-Gomez C, Nunez de Castro I, Asenjo M, Marquez J, Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation/death. Int J Biochem Cell Biol. 2002;34:439-458.
11. Coeffier M, Marion R, Ducrotte P, Dechelotte P. Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut. Clin Nutr. 2003;22:407-413.
12. Coeffier M, Marion R, Leplingard A, Lerebours E, Ducrotte P, Dechelotte P. Glutamine decreases interleukin-8 and interleukin-6 but not nitric oxide and prostaglandins e(2) production by human gut in-vitro. Cytokine. 2002;18:92-97.
13. Evans ME, Jones DP, Ziegler TR. Glutamine prevents cytokine-induced apoptosis in human colonic epithelial cells. J Nutr. 2003;133:3065-3071.
14. Bellon G, Monboisse JC, Randoux A, Borel JP. Effects of preformed proline and proline amino acid precursors (including glutamine) on collagen synthesis in human fibroblast cultures. Biochim Biophys Acta. 1987;930:39-47.
15. Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003;29:501-513.
16. Peterson D, Stanek S, Maiti B, French C, Shah A. Pharmacokinetics (PK) of Saforis administered to healthy subjects and stem cell transplant (SCT) patients with WHO grade > 2 oral mucositis (OM) [Abstract 16-115]. Support Care Cancer. 2006;14:640.
17. Aquino VM, Harvey AR, Garvin JH, et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. 2005;36:611-616.
18. Cockerham MB, Weinberger BB, Lerchie SB. Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother. 2000;34:300-303.
19. Huang EY, Leung SW, Wang CJ, et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys. 2000;46:535-539.
20. Jebb SA, Osborne RJ, Maughan TS, et al. 5-Fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer. 1994;70:732-735.
21. Schloerb PR, Skikne BS. Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. JPENJ Parenter Enteral Nutr. 1999;23:117-122.
22. Skubitz KM. Glutamine as a potential treatment for the prevention of chemotherapy-induced mucositis. J Infus Chemother. 1994;4:64-67.
23. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277-284.
24. Blijlevens NM, McCann S. Palifermin in myelotoxic therapy-induced oral mucositis: a viewpoint by Nicole M.A. Blijlevens(1) and Shaun McCann(2). Drugs. 2005;65:2147-2149.
25. Furst P, Albers S, Stehle P. Glutamine-containing dipeptides in parenteral nutrition. JPEN J Parenter Enteral Nutr. 1990;14(Suppl):118S- 124S.
26. Petit R, Shinal E, French C. AES-14 facilitates rapid intracellular transport of high levels of L-glutamine in mucosal epithelial cells [Abstract 2410]. Proc Am Soc Clin Oncol. 2000;19:612a.
27. Petit RG, Shinal E. Aesgen-14 (uptake-enhanced L-glutamine suspension) reduces severe mucositis in acute radiation model where aqueous L-glutamine suspension is ineffective [Abstract 2861]. Proc Am Soc Clin Oncol. 2002;21:261b.
28. Anderson PM, Ramsay NK, Shu XO, et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant. 1998;22:339-344.
29. Anderson PM, Schroeder G, Skubitz KM. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer. 1998;83:1433-1439.
30. Peterson DE, Petit RG. Phase III study. AES-14 in chemotherapy patients at risk for mucositis [Abstract 2917]. Proc Am Soc Clin Oncol. 2003;22:725.
31. Skubitz KM, Anderson PM. Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. J Lab Clin Med. 1996;127:223-228.
32. Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring System for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer. 1999;85:2103-2113.
33. World Health Organization. WHO handbook for reporting results in cancer treatment. Geneva, Switzerland: World Health Organization, 1979: WHO Offset Publication No. 48. Available at: http://whqlibdoc.who.int/offset/WHO_OFFSET_48. pdf Accessed on June 28, 2006.
34. Fleiss JL. The design and analysis of clinical experience. New York: John Wiley & Sons; 1986:275-279.
35. Keefe DM. Gastrointestinal mucositis: a new biological model. Support Care Cancer. 2004;12:6-9.